Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Get the Alerts
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$3.06
+7.0%		$2.89
$0.91
▼
$4.20
N/AN/AN/A203,524 shs
LIFE
Ethos Technologies Inc. Class A Common Stock
$42.53
+0.5%		$37.52
$9.45
▼
$44.99
N/AN/AN/A1.03 million shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.53
+3.2%		$0.61
$0.16
▼
$2.54
N/AN/AN/A3.26 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entera Bio Ltd. stock logo
ENTX
Entera Bio
+6.99%+1.32%+11.68%+2.00%+31.33%
LIFE
Ethos Technologies Inc. Class A Common Stock
+0.54%+3.55%+23.99%+114.36%+4,252,999,900.00%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
+3.21%+1.88%-17.22%-47.02%-60.46%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$3.06
+7.0%		$2.89
$0.91
▼
$4.20
N/AN/AN/A203,524 shs
LIFE
Ethos Technologies Inc. Class A Common Stock
$42.53
+0.5%		$37.52
$9.45
▼
$44.99
N/AN/AN/A1.03 million shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.53
+3.2%		$0.61
$0.16
▼
$2.54
N/AN/AN/A3.26 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entera Bio Ltd. stock logo
ENTX
Entera Bio
+6.99%+1.32%+11.68%+2.00%+31.33%
LIFE
Ethos Technologies Inc. Class A Common Stock
+0.54%+3.55%+23.99%+114.36%+4,252,999,900.00%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
+3.21%+1.88%-17.22%-47.02%-60.46%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Entera Bio Ltd. stock logo
ENTX
Entera Bio
2.83
Moderate Buy$9.60213.73% Upside
LIFE
Ethos Technologies Inc. Class A Common Stock
2.63
Moderate Buy$35.63-16.24% Downside
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.20
Hold$5.20881.50% Upside

Current Analyst Ratings Breakdown

Latest ENTX, OTLK, and LIFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Entera Bio Ltd. stock logo
ENTX
Entera Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/12/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Outperform
10/12/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetMarket Outperform$33.00 ➝ $40.00
10/8/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D) ➝ Sell (D+)
10/1/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeOverweight ➝ Neutral$37.00
9/24/2026
Entera Bio Ltd. stock logo
ENTX
Entera Bio
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$11.00
9/24/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$38.00
9/24/2026
Entera Bio Ltd. stock logo
ENTX
Entera Bio
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
9/23/2026
Entera Bio Ltd. stock logo
ENTX
Entera Bio
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$10.00
9/22/2026
Entera Bio Ltd. stock logo
ENTX
Entera Bio
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOverweight
9/18/2026
Entera Bio Ltd. stock logo
ENTX
Entera Bio
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$9.00
(Data available from 10/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/AN/AN/AN/AN/AN/A
LIFE
Ethos Technologies Inc. Class A Common Stock
N/AN/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/A-$0.35N/AN/AN/AN/AN/AN/A11/13/2026 (Estimated)
LIFE
Ethos Technologies Inc. Class A Common Stock
N/A-$2.85N/A31.50N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A-$0.77N/AN/AN/AN/AN/AN/A12/18/2026 (Estimated)

Latest ENTX, OTLK, and LIFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.0650N/AN/AN/AN/AN/A
8/14/2026Q3 2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.08-$0.09-$0.01-$0.15$0.97 million$0.01 million
8/7/2026Q2 2026
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.08-$0.14-$0.06-$0.14N/AN/A
8/3/2026Q2 2026
LIFE
Ethos Technologies Inc. Class A Common Stock
$0.19$0.53+$0.34$0.30N/A$189.56 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/AN/AN/AN/AN/A
LIFE
Ethos Technologies Inc. Class A Common Stock
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
14.11%
LIFE
Ethos Technologies Inc. Class A Common Stock
61.72%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%

Insider Ownership

CompanyInsider Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
3.72%
LIFE
Ethos Technologies Inc. Class A Common Stock
N/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
1.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Entera Bio Ltd. stock logo
ENTX
Entera Bio
21N/A167.45 millionOptionable
LIFE
Ethos Technologies Inc. Class A Common Stock
614N/AN/AOptionable
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
17N/A239.07 millionOptionable

Recent News About These Companies

Head-To-Head Contrast: Oncobiologics (NASDAQ:OTLK) vs. Aprea Therapeutics (NASDAQ:APRE)
October 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31131266
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
October 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/09/3378074/0/en/outlook-therapeutics-names-greg-dipasquale-chief-commercial-officer.html
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375628/0/en/outlook-therapeutics-highlights-what-the-appointment-of-new-cfo-kevin-lundquist-means-for-the-company-s-next-chapter-in-virtual-investor-discussion.html
Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Hold" from Brokerages
October 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-oncobiologics-inc-nasdaq-otlk-receives-consensus-rating-of-hold-from-brokerages-2026-10-04/
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372980/0/en/outlook-therapeutics-submits-hcpcs-level-ii-application-to-cms-for-permanent-j-code-for-lytenava-bevacizumab-vikg.html
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
September 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/11/3360236/0/en/outlook-therapeutics-fireside-chat-from-h-c-wainwright-conference-now-available-on-demand.html
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359613/0/en/outlook-therapeutics-ceo-bob-jahr-discusses-fda-approval-and-commercial-opportunity-for-lytenava-in-virtual-investor-ceo-connect-segment.html
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352397/0/en/outlook-therapeutics-appoints-kevin-lundquist-as-chief-financial-officer-as-it-prepares-for-u-s-commercial-launch-of-lytenava.html
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352076/0/en/outlook-therapeutics-ceo-bob-jahr-participates-in-the-virtual-investor-why-now-on-demand-conference.html
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
August 17, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975675/otlk-q3-earnings-call-maps-lytenava-u-s-launch-and-sales-ramp?cid=cs-stocknewsapi-ft-analyst_blog_plus|earnings_call_takeaways-2975675
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
August 15, 2026  |  defenseworld.netD
Insider Buying: Oncobiologics (NASDAQ:OTLK) Director Acquires $2,499,999.48 in Stock
August 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-otlk-insider-buying-and-selling-2026-08-15/
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936801-outlook-therapeutics-inc-otlk-q3-2026-earnings-call-transcript
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
August 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2974790/outlook-therapeutics-inc-otlk-reports-q3-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2974790
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345250/0/en/outlook-therapeutics-reports-third-quarter-fiscal-year-2026-financial-results-and-provides-business-update-highlighting-fda-approval-of-lytenava.html
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
August 14, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61200760/outlook-therapeutics-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts?utm_source=snapi
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344189/0/en/outlook-therapeutics-announces-pricing-of-55-0-million-public-offering-of-common-stock-and-warrants.html
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
August 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2972032/otlk-up-more-than-300-in-3-months-here-s-what-you-should-know?cid=cs-stocknewsapi-ft-analyst_blog|price_surge_/_plunge-2972032
Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970019/outlook-therapeutics-inc-otlk-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_9-2970019
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340307/0/en/outlook-therapeutics-to-report-third-quarter-fiscal-year-2026-financial-results-and-host-a-corporate-update-conference-call-and-webcast-on-august-14-2026.html
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
August 3, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2966678/outlook-therapeutics-to-report-q3-earnings-what-s-in-the-cards?cid=cs-stocknewsapi-ft-analyst_blog|earnings_preview-2966678

New MarketBeat Followers Over Time

Media Sentiment Over Time

Entera Bio stock logo

Entera Bio NASDAQ:ENTX

$3.06 +0.20 (+6.99%)
Closing price 10/27/2026 04:00 PM Eastern
Extended Trading
$2.96 -0.10 (-3.40%)
As of 10/27/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Ethos Technologies Inc. Class A Common Stock NASDAQ:LIFE

$42.53 +0.23 (+0.54%)
As of 10/27/2026 04:00 PM Eastern

Ethos Technologies Inc operates a technology-driven, direct-to-consumer platform for the distribution of life insurance products. Through its digital underwriting, data analytics, and proprietary technology, it enables consumers to explore, compare, and purchase life insurance policies online. The platform serves consumers, agents, and insurance carriers, and supports the application and policy issuance process through an online interface. The company works with insurance carriers to offer life insurance products in the United States through digital channels and independent agents. It generates revenue through commissions paid by carriers from policies activated and sold through its platform as well as from the provision of third-party administrator services for such policies.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$0.53 +0.02 (+3.21%)
Closing price 10/27/2026 04:00 PM Eastern
Extended Trading
$0.52 -0.01 (-1.66%)
As of 10/27/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas